Latest News for: tyk2

Edit

InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for ...

Nasdaq Globe Newswire 23 Dec 2025
CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion ... .
Edit

InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic ...

Nasdaq Globe Newswire 18 Dec 2025
The current indications under development are strategically positioned within the vast dermatology market, including AD, vitiligo, PN, CSU, and more ... .
Edit

Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in ...

Nasdaq Globe Newswire 18 Dec 2025
GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo ... .
Edit

Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals

The Elkin Tribune 11 Dec 2025
Acquisition adds a highly differentiated clinical stage asset to Formation Bio's rapidly expanding portfolio of immunology programs ... .
Edit

Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006

PR Newswire 02 Dec 2025
LNK01006 is a highly brain-penetrant, potent, and selective oral TYK2 allosteric inhibitor targeting the JH2 domain. TYK2 is a key regulator of the IL-12 and IL-23 signaling pathways, which promote Th1 and Th17 cell differentiation.
Edit

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor

Caledonian Record 28 Nov 2025
BEIJING, Nov ... 9969; SSE.
Edit

Sudo Biosciences Announces Positive Phase 1 Results for Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550

Business Wire 28 Oct 2025
CARMEL, Indiana & LONDON--(BUSINESS WIRE)-- #TYK2--Sudo Biosciences Announces Positive Phase 1 Results for Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 ... .
Edit

Galapagos NV, - Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors (Galapagos NV)

Public Technologies 24 Oct 2025
) Galapagos NV Galapagos NV ... Statutory name Galapagos NV. Title Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors. Previous result.
Edit

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors (Form 6-K) (Galapagos NV)

Public Technologies 24 Oct 2025
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors ... Inhibition of the IL-12 pathway was more pronounced for GLPG3667 than for the currently approved TYK2 inhibitor.
Edit

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors (Galapagos NV)

Public Technologies 23 Oct 2025
The data show that the in vitro pharmacological profile of GLPG3667 suggests differentiation from other TYK2 inhibitors at their clinical dose regimens ... Zasocitinib showed the most sustained inhibition of TYK2-dependent pathways.
  • 1

Article Search

tools
×
×
×
×